The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiotherapy Era

Publication date: Available online 2 October 2019Source: Practical Radiation OncologyAuthor(s): Bradford S. Hoppe, James E. Bates, Nancy P. Mendenhall, Christopher G. Morris, Debbie Louis, Meng Wei Ho, Richard Hoppe, Marwan Shaikh, Zuofeng L, Stella FlampouriAbstractBackground &PurposeMean heart dose (MHD) correlates with late cardiac toxicity among survivors of lymphoma receiving involved-field radiotherapy (IFRT). We investigated MHD and cardiac substructure dose across older and newer radiation fields and techniques to understand the value of evaluating MHD alone.Patients &MethodsFollowing IRB approval, we developed a database of dosimetry plans for 40 mediastinal lymphoma patients, which included IFRT (AP/PA), involved-site radiotherapy (ISRT) + 3-dimensional conformal radiotherapy (3DCRT), ISRT + intensity-modulated radiotherapy (IMRT), and ISRT + proton therapy plans for each patient. Each plan was evaluated for dose to the heart and cardiac substructures, including the right and left ventricles (RV, LV) and atria (RA, LA); tricuspid, mitral, and aortic valves (TV, MV, AV); and left anterior descending coronary artery (LAD). Correlation between MHD and cardiac substructure dose was assessed with linear regression. A correlation was considered very strong, strong, moderate, or weak if the r was> 0.8, 0.6-0.79, 0.4-0.59, and
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

tro V Abstract Immunotherapy has been showed as a promisor treatment, in special for hematological diseases. Chimeric antigen receptor T cells (CARs) which are showing satisfactory results in early-phase cancer clinical trials can be highlighted. However, preclinical models are critical steps prior to clinical trial. In this way, a well-established preclinical model is an important key in order to confirm the proof of principle. For this purpose, in this chapter will be pointed the methods to generate tumor cells expressing firefly Luciferase. In turn, these modified cells will be used to create a subcutaneous and...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
;o-Castro V Abstract Immunotherapy using T cells modified with chimeric antigen receptor (CAR) has been proven effective in the treatment of leukemia and lymphomas resistant to chemotherapy. Recent clinical studies have shown excellent responses of CAR-T cells in a variety of B cell tumors. However, it is important to validate in vitro activity of these cells, though different sorts of assays, which are capable of measuring the cytotoxic potential of these cells. In this chapter, it will be pointed two methods to evaluate CAR-T cell killing potential against B cell malignancy cell lines. PMID: 31707679 [PubMed - in process]
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Abstract Adoptive immunotherapy of cancer using T cells expressing chimeric antigen receptors (CARs) is now an approved treatment for non-Hodgkin lymphoma (NHL) and B cell acute lymphoblastic leukemia (B-ALL), inducing high response rates in patients. The infusion products are generated by using retro- or lentiviral transduction to induce CAR expression in T cells followed by an in vitro expansion protocol. However, use of viral vectors is cumbersome and is associated with increased costs due to the required high titers, replication-competent retrovirus (RCR) detection and production/use in a biosafety level 2 cul...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Abstract One of the most versatile gene transfer methods involves the use of recombinant lentiviral vectors since they can transduce both dividing and nondividing cells, are considered to be safe and provide long-term transgene expression since the integrated viral genome, the provirus, is passed on to daughter cells. These characteristics are highly desirable when a modified cell must continue to express the transgene even after multiple cell divisions. Lentiviral vectors are often used to introduce protein encoding cDNAs, such as reporter genes, or for noncoding sequences, such as mediators of RNA interference o...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
(Michigan Medicine - University of Michigan) For decades, a transcription factor known as STAT3 has been a major therapeutic target in the treatment of cancer, but it has largely been considered 'undruggable' due to the difficulty of developing compounds to effectively inhibit its activity. Researchers at the University of Michigan Rogel Cancer Center have taken a promising new approach to targeting STAT3 -- one that was able to achieve a long-lasting and nearly complete elimination of tumors in mouse models of leukemia and lymphoma, the authors report in Cancer Cell.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
We present a novel, TdT and CD3 negative, aggressive early T-cell precursor LBL (ETP-LBL) initially misdiagnosed as high grade B-cell lymphoma due to expression of CD79a and the erroneous detection of BCL2/IGH fusion. The patient was eventually evaluated using molecular diagnostic techniques, including fluorescence in situ hybridization (FISH) and next generation sequencing (NGS) assays that demonstrated PICALM-MLLT10 fusion and a NOTCH1 mutation in the absence of BCL2/IGH fusion. The use of NGS, specifically mate-pair sequencing (MPseq), subsequently confirmed an in-frame PICALM-MLLT10 fusion. Our retrospective analysis s...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Leukemia, Published online: 11 November 2019; doi:10.1038/s41375-019-0622-6Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47
Source: Leukemia - Category: Hematology Authors: Source Type: research
Source: Annals of Hematology - Category: Hematology Source Type: research
AbstractThe aim of this study was to evaluate the prognostic relevance of early risk stratification in diffuse large B-cell lymphoma (DLBCL) using interim Deauville score on positron emission tomography-computed tomography (PET-CT) scan and baseline International Prognostic Index (IPI). This retrospective study included 220 patients (median age, 64 years; men, 60%) diagnosed with DLBCL between 2007 and 2016 at our institution, treated with rituximab-based chemotherapy. Interim PET-CT was performed after three cycles of immuno-chemotherapy. Interim Deauville score was assessed as 4 or 5 in 49 patients (22.3%), and 94 patien...
Source: Annals of Hematology - Category: Hematology Source Type: research
Publication date: Available online 9 November 2019Source: Pharmacology &TherapeuticsAuthor(s): Wen-juan Liu, Yue Du, Ru Wen, Ming Yang, Jian XuAbstractRapidly developing molecular biology techniques have been employed to identify cancer driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors and antibodies that specifically target driver gene-mediated signaling pathways to suppress tumor growth and progression are expected to extend the survival time and further improve the quality of life of patients. However, the health of patients with advanced and metastatic NSCLC presents signif...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Cardiology | Databases & Libraries | Heart | Intensity-Modulated Radiation Therapy | Lymphoma | Men | Proton Therapy | Toxicology